Haploidentical Hematopoietic Cell Transplantation in Lymphomas

  • Guru Subramanian Guru Murthy
  • Mehdi Hamadani
  • Parameswaran N. Hari
Part of the Advances and Controversies in Hematopoietic Transplantation and Cell Therapy book series (ACHTCT)


Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative salvage treatment for patients with lymphoproliferative disorders (LPDs). In the United States, it is estimated that about 19,790 patients with non-Hodgkin lymphoma (NHL) and 1150 patients with Hodgkin lymphoma died in the calendar year of 2015. Progressive disease is a leading cause of mortality in patients with lymphomas. Although allo-HCT appears to be an attractive treatment option for patients with advanced lymphomas, its widespread application is often limited by factors such as HLA-matched donor availability and the risk of post-transplant morbidity. Haploidentical HCT (haplo-HCT) expands the allo-HCT strategy to patients without an available fully HLA-matched adult donor, while novel haplo-HCT techniques have improved the safety of this approach. Historically, in the haploidentical setting, severe graft-versus-host disease (GvHD), higher risk of non-relapse mortality (NRM), disease relapse, and delayed immune reconstitution were challenges despite extensive in vivo or ex vivo T-cell depletion aimed at reduced graft rejection and GvHD risk. More recently, several Asian centers have reported favorable outcomes of haplo-HCT utilizing T-cell replete grafts with intensive immunosuppression using antithymocyte globulin (ATG). A different strategy of T-cell replete haplo-HCT being increasingly used involves the administration of high-dose post-transplantation cyclophosphamide (PTCy), which mitigates the risk of GvHD by targeting alloreactive T-cells rapidly proliferating early after HLA-mismatched transplant while sparing regulatory T-cells and hematopoietic progenitor cells. The near universal and ease of haploidentical donor availability have led to a rapid adoption of this strategy in patients with LPDs.


Haploidentical transplants Post-transplant cyclophosphamide NMA Myeloablative Relapse GvHD Lymphoma HL NHL Conditioning 


  1. 1.
    National Cancer Institute. SEER stat fact sheet: Hodgkin’s lymphoma. Accessed 2016.Google Scholar
  2. 2.
    National Cancer Institute. SEER stat fact sheet: non-Hodgkin’s lymphoma. Accessed 2016.Google Scholar
  3. 3.
    Favier O, Heutte N, Stamatoullas-Bastard A, et al. Survival after Hodgkin lymphoma: causes of death and excess mortality in patients treated in 8 consecutive trials. Cancer. 2009;115(8):1680–91.CrossRefGoogle Scholar
  4. 4.
    Reisner Y, Aversa F, Martelli MF. Haploidentical hematopoietic stem cell transplantation: state of art. Bone Marrow Transplant. 2015;50(Suppl 2):S1–5.CrossRefGoogle Scholar
  5. 5.
    Fuchs EJ. Haploidentical transplantation for hematologic malignancies: where do we stand? Hematology Am Soc Hematol Educ Program. 2012;2012:230–6.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Wang Y, Liu DH, Liu KY, et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer. 2013;119(5):978–85.CrossRefGoogle Scholar
  7. 7.
    Fuchs EJ. HLA-haploidentical blood or marrow transplantation with high-dose, post-transplantation cyclophosphamide. Bone Marrow Transplant. 2015;50(Suppl 2):S31–6.CrossRefGoogle Scholar
  8. 8.
    Hamadani M, Craig M, Awan FT, Devine SM. How we approach patient evaluation for hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010;45(8):1259–68.CrossRefGoogle Scholar
  9. 9.
    Raiola A, Dominietto A, Varaldo R, et al. Unmanipulated haploidentical BMT following nonmyeloablative conditioning and post-transplantation CY for advanced Hodgkin's lymphoma. Bone Marrow Transplant. 2014;49(2):190–4.CrossRefGoogle Scholar
  10. 10.
    Kanakry JA, Kasamon YL, Gocke CD, et al. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant. 2013;19(4):602–6.CrossRefGoogle Scholar
  11. 11.
    Kasamon YL, Bolaños-Meade J, Prince GT, et al. Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. J ClinOncol. 2015;33(28):3152–61.CrossRefGoogle Scholar
  12. 12.
    Farina L, Bruno B, Patriarca F, et al. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or nonmyeloablative allogeneic stem cell transplantation. Leukemia. 2009;23(6):1131–8.CrossRefGoogle Scholar
  13. 13.
    Chang YJ, Luznik L, Fuchs EJ, Huang XJ. How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation? J Hematol Oncol. 2016;9:35.CrossRefGoogle Scholar
  14. 14.
    Wang Y, Chang YJ, LP X, et al. Who is the best donor for a related HLA haplotype-mismatched transplant? Blood. 2014;124(6):843–50.CrossRefGoogle Scholar
  15. 15.
    Ciurea SO, Champlin RE. Donor selection in T cell-replete haploidentical hematopoietic stem cell transplantation: knowns, unknowns, and controversies. Biol Blood Marrow Transplant. 2013;19(2):180–4.CrossRefGoogle Scholar
  16. 16.
    Bashey A, Zhang X, Jackson K, et al. Comparison of outcomes of hematopoietic cell transplants from t-replete haploidentical donors using post-transplantation cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched unrelated donors and HLA-identical sibling donors: a multivariable analysis including disease risk index. Biol Blood Marrow Transplant. 2016;22(1):125–33.CrossRefGoogle Scholar
  17. 17.
    Brammer JE, Khouri I, Gaballa S, et al. Outcomes of haploidentical stem cell transplantation for lymphoma with melphalan-based conditioning. Biol Blood Marrow Transplant. 2016;22(3):493–8.CrossRefGoogle Scholar
  18. 18.
    Hamadani M, Saber W, Ahn KW, et al. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biol Blood Marrow Transplant. 2013;19(5):746–53.CrossRefGoogle Scholar
  19. 19.
    Hamadani M, Saber W, Ahn KW, et al. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2013;19(4):625–31.CrossRefGoogle Scholar
  20. 20.
    Fenske TS, Ahn KW, Graff TM, et al. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Br J Haematol. 2016;174(2):235–48. Scholar
  21. 21.
    Bacher U, Klyuchnikov E, Le-Rademacher J, et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood. 2012;120(20):4256–62.CrossRefGoogle Scholar
  22. 22.
    McCurdy SR, Kanakry JA, Showel MM, et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose post transplantation cyclophosphamide. Blood. 2015;125(19):3024–31.CrossRefGoogle Scholar
  23. 23.
    Kanakry JA, Gocke CD, Bolaños-Meade J, et al. Phase II study of nonmyeloablative allogeneic bone marrow transplantation for B cell lymphoma with post-transplantation rituximab and donor selection based first on non-HLA factors. Biol Blood Marrow Transplant. 2015;21(12):2115–22.CrossRefGoogle Scholar
  24. 24.
    Kanate AS, Mussetti A, Kharfan-Dabaja MA, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016;127(7):938–47.CrossRefGoogle Scholar
  25. 25.
    Burroughs LM, O'Donnell PV, Sandmaier BM, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14(11):1279–87.CrossRefGoogle Scholar
  26. 26.
    Karmali R, Ghosh N, Rocha G, et al. Survival after T-cell replete haploidentical related donor hematopoietic cell transplantation (Haplo-HCT) using post-transplant cyclophosphamide (PT-CY) compared with HLA-matched related donor (MRD) transplant for lymphomas. Biol Blood Marrow Transplant. 2016;22(3):S75–6.CrossRefGoogle Scholar
  27. 27.
    Dietrich S, Finel H, Martinez C, et al. Haplotransplants versus other alternative donors for allogeneic stem cell transplantation in non Hodgkin lymphoma (NHL): a retrospective analysis of the EBMT Lymphoma Working Party. ASH 2014 annual meeting abstract. Blood. 2014;124:2573.CrossRefGoogle Scholar
  28. 28.
    Martinez C, Gayoso J, Canals C, et al. Alternative donors (umbilical cord blood and haploidentical donors) for allogeneic stem cell transplantation in relapsed/refractory hodgkin lymphoma: a retrospective analysis of the EBMT Lymphoma Working Party and the Spanish Group of Stem Cell Transplantation (GETH). ASH 2015 annual meeting abstract. Blood. 2015;126:4399.Google Scholar
  29. 29.
    Castagna L, Bramanti S, Furst S, et al. Nonmyeloablative conditioning, unmanipulatedhaploidentical SCT and post-infusion CY for advanced lymphomas. Bone Marrow Transplant. 2014;49(12):1475–80.CrossRefGoogle Scholar
  30. 30.
    Zeidan AM, Forde PM, Symons H, et al. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2014;20(3):314–8.CrossRefGoogle Scholar
  31. 31.
    Huang XJ. Immunomodulatory strategies for relapse after haploidentical hematopoietic stem cell transplantation in hematologic malignancy patients. Best Pract Res Clin Haematol. 2011;24(3):351–8.CrossRefGoogle Scholar
  32. 32.
    Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–50.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Guru Subramanian Guru Murthy
    • 1
  • Mehdi Hamadani
    • 1
    • 2
  • Parameswaran N. Hari
    • 1
    • 2
  1. 1.Division of Hematology and OncologyMedical College of WisconsinMilwaukeeUSA
  2. 2.Center for International Blood and Marrow Transplant ResearchMilwaukeeUSA

Personalised recommendations